Welcome to Optimum TV!
Optimum TV brings you bitesize content from life science leaders – talking trends, innovation, capital markets and more…
Tune in, subscribe and share.
Episode 68
M Ventures: What do investors want?
With Hakan Goker, Managing Director, M Ventures
Episode 67
BioCentury: Resiliency in the face of volatility
With Stephen Hansen, Director of Biopharma Intelligence at BioCentury
Episode 66
R1 Therapeutics: a new kidney biotech focusing on phosphate removal
With Krishna Polu, CEO of R1 Therapeutics
Episode 65
Babraham: From cowsheds to cancer cures
With Dr Louise Jopling, Chief Scientific and Innovation Officer, Babraham Research Campus
Episode 64
How ‘NMR’-based metabolomic biomarkers can help spot diseases earlier
With Florian Voss, CEO, numares Health
Episode 63
Tackling fibrotic kidney diseases
With William Newsome, President and CEO, Fibrocor Therapeutics
Episode 62
Thought Leaders 2026: Merck, Keytruda, and “the mother of all patent cliffs”. Or is it?
With John Murphy and Aude Gerspacher, Bloomberg Intelligence
Episode 61
Dealmakers 2026: Capital, M&A, and biotech’s next wave
With Giovanni Mariggi, Co-founder and Partner, Medicxi
Episode 60
Dealmakers 2026: How Biotechs can stand out in 2026
With Anja Harmeier, Head of Roche Venture Fund
Episode 59
Dealmakers 2026: Is Medtech the next investment upswing?
With Hugo Harrod, MVM Partners
Episode 58
Dealmakers 2026: Things can only get better
With Clara Campàs, Co-founder and Managing Partner, Asabys Partners
Episode 57
Dealmakers 2026: Will ‘Pharma FOMO’ boost the life sci market in 2026?
With Otello Stampacchia, founder and Managing Director, Omega Funds
Episode 56
Transforming transplant potential
With Renée Aguiar-Lucander, CEO, Hansa Biopharma
Episode 55
Dealmakers 2026: How to stand out in a crowded field
With Mary Clark, CEO, Optimum Strategic Communications
Episode 54
Transforming Hemodialysis: aXess leads the way
With Paulo Neves, Chief Medical Officer of Xeltis
Episode 53
London Life Sciences Week 2025: Unlocked
With Mary Clark, Optimum and Arnaldo De Lisio, Catalyst Advisors
Episode 52
Developing a first-in-class drug for Fragile X Syndrome
With Dr, Josep Prous Jr, Co-Founder & CSO of CONNECTA Therapeutics
Episode 51
Tackling chronic skin conditions with virus-like particles (VLPs)
With Dr Steven Powell, CEO and Co-founder of Glen Clova Scientific
Episode 50
Turning on the taps using upfront royalties
With Clarke Futch, Chairman and CEO of HealthCare Royalty Partners
Episode 49
Countdown to Conference: “picking winners” with conviction
With Antoine Papiernik, Managing Partner at Sofinnova Partners
Episode 48
Countdown to Conference: Resilience during market turbulence
With Søren Møller, Managing Partner, Novo Holdings Seed Investments
Episode 47
Countdown to Conference: the importance of junior VCs
With Philip Brainin, Associate at Sound Bioventures
Episode 46
Developing a pill for diabetic retinopathy
With Ulrik Mouritzen, CEO of Breye Therapeutics
Episode 45
The growing potential of ‘off-the-shelf’ stem cell treatments
With Dr Søren Sheikh, CEO of Blue Cell Therapeutics
Episode 44
Optimum Thought Leaders: Bridging the divide between bio and tech investing
With Barbara Domayne-Hayman, Entrepreneur-in-Residence at the Francis Crick Institute and Co-founder and Chair of KQ Labs
Episode 43
Optimum Dealmakers: Forty-five years in biopharma has taught me this
With Göran Ando, former Chairman of Novo Nordisk’s Board of Directors
Episode 42
Optimum Dealmakers: Getting closer to the front lines of innovation
With Felice Verduyn – van Weegen, Partner, EQT Life Sciences
Episode 41
Optimum Thought Leaders: How the challenging financing environment is reshaping biotech
With Melanie Senior, biopharma journalist for the Nature portfolio and Evaluate
Episode 40
How Splice Bio landed a $135m Series B to advance its genetic medicines
With Miquel Vila-Perelló, Co-founder and CEO of Splice Bio, and Daniela Begolo, Managing Director at EQT Life Sciences
Episode 39
How V-Bio is championing true life science innovators
With Christina Takke, Co-founder and Managing Partner of V-Bio Ventures
Episode 38
The potential of supramolecular polymers for a PFAS-free future of medicine
With Professor Bert Meijer
Episode 37
Why the immuno-dermatology space is heating up
With Thibaud Portal and Brian Kim of Alys Pharmaceuticals
Episode 36
Crimson Gateway: Opening up China’s new world of biotech companies
With Lan Zhang, CEO of Crimson Gateway
Episode 35
How to free up tens of billions trapped in the wrong place
With Nicholas Johnston, Founder & Board Member of Alis Biosciences
Episode 34
Optimum Dealmakers: “No IPO? No problem.” Financing options during today’s IPO drought
With Mårten Steen, Managing Partner at HealthCap
Episode 33
Optimum Dealmakers: How to make your own luck
With Edwin Moses, seasoned NED and ex-CEO of Ablynx
Episode 32
What is Huntington’s disease – and how are the treatment approaches changing?
With David Reynolds, CEO of LoQus23 Therapeutics
Episode 31
Optimum Dealmakers: Brandon Capital – How Australasia’s leading life-science focused VC is spreading its wings in Europe and the US
With Jonathan Tobin, Partner, Brandon Capital
Episode 30
Optimum Dealmakers: Syncona – A long term approach to funding ambitious life science companies
With Roel Buthuis, Managing Partner, Syncona
Episode 29
Creating a universal vaccine to protect against pneumococcal disease
With Neil Murray, CEO of ReNewVax
Episode 28
The hidden dangers of PFAS in medical grafts
With Professor Frans Moll
Episode 27
Frontotemporal dementia (FTD): the challenge of diagnosis and the care journey
With Katie Brandt, Director of Caregiving Support Services at Massachusetts General Hospital’s Frontotemporal Dementia Unit
Episode 26
From small biotech to billion-dollar company
With Renée Aguiar-Lucander, former CEO of Calliditas Therapeutics
Episode 25
Targeted cell depletion using highly programmable RNA-guided nuclease technology
With Lukas Linnig and Michael Krohn, Co-CEOs, Akribion Therapeutics
Episode 24
Making sustainable textiles from microbes
With Ulrich Scherbel, CEO of AMSilk
Episode 23
How is the life science market shaping up in 2025?
With Dale Raine, Global Co-head of Biopharma at Lazard
Episode 22
Xeltis outlines plans for aXess, its revolutionary vascular access conduit for dialysis
With Eliane Schutte, CEO of Xeltis
Episode 21
Survey of EU Life Sciences investors representing c.$300bn of assets
With Hollie Vile, Optimum Strategic Communications
Episode 20
Sequana Medical’s alfapump® recieves FDA approval
With Ian Crosbie, CEO of Sequana Medical
Episode 19
Creating targeted therapeutic vaccines that stop cancer in its tracks
With Jonathan Kwok, CEO and Co-Founder of Infinitopes
Episode 18
Muscular Dystrophy: The reality of living with a rare disease
With Tahira Mathur, Patient advocate for Muscular Dystrophy UK
Episode 17
Targeting brain cancer using a high-precision radiopharmaceutical
With Greg Mullen, COO of Ariceum Therapeutics
Episode 16
A novel way to tackle Huntington’s disease
With David Reynolds, CEO of LoQus23 Therapeutics
Episode 15
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 5
With Allan Marchington, MD and Head of Life Sciences at ICG
Episode 14
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 4
With Francesco De Rubertis, Co-Founder and Partner at Medicxi
Episode 13
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 3
With Dr Daniel Mahony, Partner at Novo Holdings
Episode 12
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 2
With Geraldine O’Keeffe, Partner at EQT
Episode 11
The Optimum TV ‘Countdown-to-Conference’ mini-series – Part 1
With Kieran Murphy, Chair of Gamma Biosciences, SPT Labtech and Centiva
Episode 10
How a pill can boost the chance of having a baby following IVF / ICSI fertility treatment
With Dr Agnès Arbat, Co-Founder and CEO of Oxolife
Episode 9
How does a British biotech raise £90m in a Series A? It’s as easy as ADC.
With Michael Bauer, Partner at Novo Holdings Venture Investments
Episode 8
New treatment beckons for cutaneous T-cell lymphoma (CTCL)
With Jason Loveridge, CEO of 4SC
Episode 7
Creating exceptional antibody-based drugs by interrogating the immune responses of ‘elite responders’ to disease
Joined by Stefano Gullà, CSO of Kling Biotherapeutics
Episode 6
Harnessing the body’s complement system to tackle cancer and autoimmune disease
Joined by Krishna Polu, CEO of Commit Bio
Episode 5
Modifying RNA with small molecule drugs: a new approach to immunotherapy
Joined by Jerry McMahon, CEO of STORM Therapeutics
Episode 4
How to “build” a new blood vessel- the natural way
Joined by Eliane Shutte, CEO of Xeltis
Episode 3
Using cell therapy to revolutionise treatment of end-stage liver disease
Joined by Amir Hefni, CEO of Resolution Therapeutics
Episode 2
How to get the most out of the 2024 spring conference season
Joined by Nick Bastin, Optimum Strategic Communications
Episode 1
Has spring finally sprung for biotech markets?
Joined by Eva Haas, Optimum Strategic Communications
